OBJECTIVE: To systematically review the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors versus glucagon like peptide-1 (GLP-1) receptor agonists for type 2 diabetes mellitus (T2DM). METHODS: Databases including EMbase, PubMed, The Cochrane Library, Clinical Trial, CBM, CNKI and WanFang Data, were searched electronically for randomized controlled trials (RCTs) of DPP-4 inhibitors versus GLP-1 receptor agonists for T2DM up to December 2015. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then Meta-analysis was performed using RevMan 5.3 soft ware. RESULTS: A total of 13 RCTs were included. The results of Meta-analysis showed that compared with DPP-4- inhibitors, GLP-1 receptor agonists were more effective in reducing the levels of fasting plasma glucose [MD = 0.93, 95% CI (0.48, 1.38), P < 0.0001] and glycated hemoglobin [ MD = 0.53, 95% CI (0.34, 0.73), P<0.00001] andBMI [MD = 1.53, 95% CI(0.83, 2.22), P <0.001]. However, DPP-4 inhibitors were more effective than GLP-1 receptor agonists in the reducing the 2-hour postprandial blood glucose level. And GLP-1 receptor agonists were more prone to cause gastrointestinal adverse reactions than DPP-4 inhibitors [RR =0.44,95% CI (0.33, 0.59), P <0.0001]. CONCLUSION GLP-1 receptor agonists are superior to DPP-4 inhibitors in controlling the fasting plasma glucose and glycated hemoglobin levels and reducing the body weight of T2DM patients, while DPP-4 inhibitors have better efficacy in reducing 2-hour postprandial blood glucose level, with better tolerability.

Focused on nanobiology and nanomedicine, this article elucidates its main research targets and contents, discusses the important of researches in this field, introduces the tasks and objectives of the corresponding researches in the national long- and mid-term science and technology development planning, and also describes the present research status in China.
Biology ; trends ; China ; Nanomedicine ; trends ; Nanotechnology ; trends

3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) is a synthetic khellactone ester that exhibits potent anti-HIV activity with a mechanism distinct from clinically used anti-HIV agents. Several series of DCK analoges have been synthesized and evaluated for inhibitory effects against HIV. This review article describes recent progress in the discovery, structural modification, and structure-activity relationship studies of potent anti-HIV DCK derivatives.
Anti-HIV Agents ; chemical synthesis ; chemistry ; pharmacology ; Biological Availability ; Camphor ; analogs & derivatives ; chemical synthesis ; chemistry ; pharmacology ; Coumarins ; chemical synthesis ; chemistry ; pharmacology ; HIV ; drug effects ; HIV Reverse Transcriptase ; antagonists & inhibitors ; Humans ; Lactones ; chemical synthesis ; chemistry ; pharmacology ; Structure-Activity Relationship

OBJECTIVETo investigate the predictive value of HCV RNA in PBMC of patients with chronic hepatitis C to IFN treatment.

METHODSThe HCV RNAs in PBMC were detected at the end of treatment, and 24 week and 1 year follow up after end treatment, in 16 patients who acquired complete response to IFN in 12 weeks of 24 weeks therapy.

RESULTS9 patients were HCV RNA positive in their PBMC at the end of treatment, the serum HCV RNA of 8 turned positive after 24 weeks and 1 year follow-up. In 7 patients with negative HCV RNA in PBMC, only two patients relapsed in serum HCV RNA after 1 year follow-up, and others remained viral response after 3.5 years.

CONCLUSIONHCV RNA in PBMC at the end of treatment was a predictor of the durable response to antiviral therapy in chronic hepatitis C.

Adult ; Female ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Leukocytes, Mononuclear ; virology ; Male ; Middle Aged ; RNA, Viral ; blood ; Recombinant Proteins

OBJECTIVETo study whether the abilities of hepatitis C virus (HCV) E2 gene immunization to induce humoral and cellular immune responses to E2 protein were affected by hepatitis B virus (HBV) preS gene when they fused in DNA-immunized mice.

METHODSMice were immunized with E2, preS-E2 (preS gene was upstream of E2 gene), and E2-preS (preS gene was downstream of E2 gene) gene by their eukaryotic expression vectors, respectively. The anti-E2 or anti-preS antibodies were detected using the E2 and preS antigens. The cellular immune response to E2 protein in immunized mice was presented by its survival time after injecting SP2/O myeloma cells expressing HCV E2 protein into the abdominal cavity.

RESULTSChimeric E2 and preS gene immunization can induce mice to develop anti-preS and anti-E2 antibodies. The number of the mice developing anti-E2 antibody and the antibody titers in preS-E2 gene-injected group were higher than those in E2-preS gene-immunized group. However, the mice injected with E2 gene did not develop the detectable anti-E2 antibodies until 12 weeks after DNA immunization. After the mice was injected with target cells, the average survival time of the mice in the group immunized with E2 gene alone was longer than that of the group injected with E2 gene fused with HBV preS and was significantly longer than that of the control (P < 0.05).

CONCLUSIONHBV preS might be a humoral enhancer that can affect the abilities of HCV E2 protein to induce immune responses in DNA-immunized mice.

Animals ; Antibody Formation ; drug effects ; Hepacivirus ; chemistry ; Hepatitis B Surface Antigens ; genetics ; pharmacology ; Hepatitis B virus ; chemistry ; genetics ; Immunity, Cellular ; drug effects ; Male ; Mice ; Mice, Inbred BALB C ; Protein Precursors ; genetics ; pharmacology ; Recombinant Fusion Proteins ; immunology ; Viral Envelope Proteins ; genetics ; pharmacology

Nowadays, many clinical studies have demonstrated that some patients can achieve the reversal of liver cirrhosis. Therefore, the methods for accurate assessment of whether the reversal of liver cirrhosis can be achieved and when it is achieved have become the hotspots in clinical research. This helps with the specific evaluation of therapeutic outcome, the adjustment of treatment regimen, and the prediction of prognosis. This article introduces the application of various indices after the reversal of liver cirrhosis due to different etiologies from the aspects of noninvasive models and liver biopsy, in order to search for the methods that can accurately reflect the features of reversal.

Cholestatic liver disease is caused by the damage of bile duct cells and hepatocytes due to bile duct injury, accumulation of bile acids, and persistent inflammation. If it is not treated in time, cholestasis can lead to liver fibrosis, liver cirrhosis, and even end-stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common cholestatic liver diseases in adults, with unknown causes. Although ursodeoxycholic acid (UDCA) can improve the prognosis of PBC patients and prolong survival time after liver transplantation, some patients have no response to UDCA. In addition, there are still no effective pharmacotherapies for PSC. With the research advances in molecular mechanism of bile acid regulation and a deeper understanding of immune pathways in recent years, several new drugs have emerged. This article introduces the new therapeutic targets and drugs for PBC and PSC.

OBJECTIVETo observe the effects of Xiaochaihu decoction and different herbal formulation of componenton on inhibiting H22 mouse solid liver cancer and on the immune function, for approaching the dose-effect relationship and compatibility mechanism.

METHODTransplanted H22 liver the cancer to mice, filling on high, moderate, low dose of mice in the xiaochaihu decoction drug (27, 13.5, 6.75 g x kg(-1)), 5-FU intraperitoneal injection (20 mg x kg(-1)) as positive control. After being administered for 10 days, we determined the cancer weight, body weight, spleen index and thymus gland index for studying the dose-effect relationship. And we studied compatibility rule of Xiaochaihu decoction and the different herbal formulations of its components by using the same method. Mice in the Xiaochaihu decoction group (13.5 g x kg(-1)) and Ginseng-Chinese Date-Licorice Root apozem group (5 g x kg(-1)) were given the medicines for 10 days to observe the weight of tumor, body weight, spleen index, the NK cell activity, proliferation of the T lymphocytes and IL-2 level.

RESULTGrowth of H22 mouse liver cancer was markedly inhibited in high, moderate, low dose group; the inhibiting rates were 49.66%, 48.52%, 36.91%, respectively; the optimal administration dose was moderate. In the study of compatibility rule, only inhibiting rates of Ginseng-Chinese Date-Licorice Root apozem group and Xiaochaihu decoction group exceed 30%; the inhibiting rates were 41.55% and 43.65%. As compared with normal group, spleen index of three dose groups and the different herbal formulation groups was evidently increased (P < 0.01); thymus gland index of the different herbal formulation groups was significant decreased (P < 0.05); thymus gland index and body weight of 5-FU group were evidently decreased (P < 0.001). As compared the model group, the NK cell activity, proliferation of the T lymphocytes and IL-2 level of Xiaochaihu decoction were remarkably increased (P < 0.001); the NK cell activity and IL-2 level of Ginseng-Chinese Date-Licorice Root group were remarkably increased (P < 0.05); the NK cell activity and proliferation of the T lymphocytes and IL-2 level of 5-FU group were remarkable decreased (P < 0.01). As comparing with the normal control group ,body weight of 5-FU group was evidently decreased (P < 0.05).

CONCLUSIONXiaochaihu decoction and Ginseng-Chinese Date-Licorice Root group can markedly inhibit the growth of H22 mouse solid liver cancer and improve the immune function of tumor-bearing mice. The inhibiting effect probably closely related with improving the tumor-bearing host immune function. There is a hint that compatibility Ginseng-Chinese Date-Licorice Root of strengthening body resistance is the core of inhibiting effect.

Animals ; Dosage Forms ; Drugs, Chinese Herbal ; chemistry ; pharmacology ; therapeutic use ; Glycyrrhiza ; chemistry ; Immunity, Cellular ; drug effects ; Interleukin-2 ; metabolism ; Killer Cells, Natural ; drug effects ; metabolism ; Liver Neoplasms, Experimental ; drug therapy ; Male ; Mice ; Panax ; chemistry ; T-Lymphocytes ; drug effects ; metabolism

OBJECTIVETo observe the renal function, histology and the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) in rats administered with Aristolochi manshriensis (AM) and Longdan Xiegan decoction (LDXG) containing AM.

METHODDivided SD rats into control, AM and LDXG groups (n = 10 per group) at random and administrated orally for 8 weeks with distilled water, AM (6 g x kg(-1) x d(-1)) and LDXG (17. 5 g x kg(-1) x d(-1), containing AM 6 g x kg(-1) x d(-1)), respectively. Measured renal functional parameters in serum, urine and IL-1beta, IL-6 in renal homogenate, and observe renal histologic lesions at the end of 8 weeks.

RESULTTwo kinds of water abstract induced significantly renal injury in rats, IL-1beta, IL-6 levels in renal homogenate were significantly increased compared with controls, histological section showed inflammatory cell infiltration play important role in renal tubulointerstitium damage. LDXG caused less seriously damage than AM.

CONCLUSIONAM and LDXG in experimental dosage can induce renal injury, inflammatory cell infiltration in renal tubulointerstitium and high levels of IL-1beta, IL-6 presumpt that the nephrotoxicity of AM and LDXG refered to the immune mechanism. LDXG has light nephrotoxicity due to its restraining the inflammatory reaction caused by AM.

Administration, Oral ; Animals ; Aristolochia ; chemistry ; Blood Urea Nitrogen ; Creatinine ; blood ; Drug Combinations ; Drugs, Chinese Herbal ; administration & dosage ; isolation & purification ; toxicity ; Interleukin-1beta ; metabolism ; Interleukin-6 ; metabolism ; Kidney ; drug effects ; metabolism ; pathology ; Kidney Tubules ; drug effects ; metabolism ; pathology ; Male ; Plants, Medicinal ; chemistry ; Proteinuria ; blood ; chemically induced ; Random Allocation ; Rats ; Rats, Sprague-Dawley

Antiviral Agents ; therapeutic use ; Hepatitis C, Chronic ; drug therapy ; Humans ; Ribavirin ; therapeutic use